Parsons Capital Management’s Entero Therapeutics ENTO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-1
| Closed | -$2K | – | 421 |
|
|
2022
Q2 | $2K | Hold |
1
| – | – | ﹤0.01% | 410 |
|
|
2022
Q1 | $11K | Hold |
1
| – | – | ﹤0.01% | 423 |
|
|
2021
Q4 | $15K | Hold |
1
| – | – | ﹤0.01% | 436 |
|
|
2021
Q3 | $47K | Hold |
1
| – | – | ﹤0.01% | 419 |
|
|
2021
Q2 | $138K | Hold |
1
| – | – | 0.01% | 418 |
|
|
2021
Q1 | $225K | Hold |
1
| – | – | 0.02% | 384 |
|
|
2020
Q4 | $163K | Hold |
1
| – | – | 0.01% | 369 |
|
|
2020
Q3 | $127K | Hold |
1
| – | – | 0.01% | 343 |
|
|
2020
Q2 | $161K | Sell |
1
-1
| -50% | -$161K | 0.02% | 326 |
|
|
2020
Q1 | $164K | Sell |
2
-1
| -33% | -$82K | 0.02% | 302 |
|
|
2019
Q4 | $328K | Hold |
3
| – | – | 0.03% | 287 |
|
|
2019
Q3 | $259K | Hold |
3
| – | – | 0.03% | 304 |
|
|
2019
Q2 | $735K | Hold |
3
| – | – | 0.08% | 211 |
|
|
2019
Q1 | $1.04M | Hold |
3
| – | – | 0.11% | 173 |
|
|
2018
Q4 | $524K | Hold |
3
| – | – | 0.06% | 228 |
|
|
2018
Q3 | $1.12M | Hold |
3
| – | – | 0.12% | 165 |
|
|
2018
Q2 | $1.1M | Hold |
3
| – | – | 0.13% | 160 |
|
|
2018
Q1 | $1.04M | Buy |
3
+1
| +50% | +$345K | 0.12% | 169 |
|
|
2017
Q4 | $997K | Hold |
2
| – | – | 0.11% | 179 |
|
|
2017
Q3 | $1.02M | Buy |
2
+1
| +100% | +$508K | 0.12% | 170 |
|
|
2017
Q2 | $745K | Hold |
1
| – | – | 0.09% | 207 |
|
|
2017
Q1 | $323K | Hold |
1
| – | – | 0.04% | 280 |
|
|
2016
Q4 | $397K | Buy |
+1
| New | +$397K | 0.05% | 248 |
|